Advanced in Ewing Sarcoma
Advanced in Ewing Sarcoma
2142 N Cove Blvd, 5 West Pediatrics, 
Toledo, OH 

Overview

Jamie Dargart is a Pediatric Hematologist Oncology provider in Toledo, Ohio. Dr. Dargart is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Hepatoblastoma, Reticulohistiocytoma, Histiocytosis, Langerhans Cell Histiocytosis, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 3 peer reviewed articles and participating in 53 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has participated in 11 clinical trials in the study of Ewing Sarcoma.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in IL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Paramount
  • EPO
  • HMO
  • INDEMNITY
  • PPO
Priority Health
  • HMO
  • POS
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

2142 N Cove Blvd, 5 West Pediatrics, Toledo, OH 43606

Additional Areas of Focus

Dr. Dargart has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


53 Clinical Trials

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)
Renal Tumors Classification, Biology, and Banking Study
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years
View 49 Less Clinical Trials
Similar Doctors
Elite in Ewing Sarcoma
Pediatric Hematology Oncology
Elite in Ewing Sarcoma
Pediatric Hematology Oncology
1500 E Medical Center Dr, 
Ann Arbor, MI 
 (42.6 miles away)
Languages Spoken:
English

Patrick Grohar is a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Grohar is rated as a Distinguished provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Ewing Sarcoma, Osteosarcoma, Adult Soft Tissue Sarcoma, and Rhabdoid Tumor.

Advanced in Ewing Sarcoma
Pediatric Hematology Oncology
Advanced in Ewing Sarcoma
Pediatric Hematology Oncology
2213 Cherry St, 
Toledo, OH 
 (2.7 miles away)
Languages Spoken:
English

Nicholas Yeager is a Pediatric Hematologist Oncology provider in Toledo, Ohio. Dr. Yeager is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. His top areas of expertise are Osteosarcoma, Ewing Sarcoma, Adult Soft Tissue Sarcoma, and Rhabdomyosarcoma.

Advanced in Ewing Sarcoma
Pediatrics | Pediatric Hematology Oncology | Hematology
Advanced in Ewing Sarcoma
Pediatrics | Pediatric Hematology Oncology | Hematology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (42.8 miles away)
Languages Spoken:
English

Rama Rao is a Pediatrics specialist and a Pediatric Hematologist Oncology provider in Ann Arbor, Michigan. Dr. Rao is rated as an Advanced provider by MediFind in the treatment of Ewing Sarcoma. Her top areas of expertise are Osteosarcoma, Chondrosarcoma, Neuroblastoma, Hereditary Neuroblastoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Dargart's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 8 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile